| Literature DB >> 34187301 |
Aneisha Collins-Fairclough1,2, Robine Donken3,4,5, Bohdan Nosyk1, Simon Dobson3, Gina Ogilivie4,5, Manish Sadarangani3,6.
Abstract
Protection after human papillomavirus (HPV) vaccination can be maximized by optimizing vaccination schedules. We systematically reviewed immunogenicity and effectiveness of HPV vaccines administered 6 months apart compared with longer intervals. Seroconversion to vaccine-type HPV was non-inferior for 12- compared with 6-month intervals, but inconclusive for comparison of 36-96 months with 6 months. A 12-month interval showed non-inferior (margin 0.5) vaccine-type HPV antibody responses compared with a 6-month interval. Compared to 6 months, an interval of 36-96 months resulted in non-inferior antibody responses for HPV6 and high-risk types HPV16 and 18, but did not lead to a non-inferior antibody response for HPV11 (GMR 0.63, 95% CI:0.41-0.97). Data on the effectiveness of extended two-dose schedules were limited. Our findings indicate that HPV immunization programs could adopt a 12-month interval instead of 6 months for increased flexibility without compromising immunogenicity. Further evaluation to confirm the immunogenicity and effectiveness of intervals beyond 12 months is warranted.Entities:
Keywords: Antibody levels; extended intervals; human papillomavirus vaccine; immunization schedule; non-inferiority; two-dose schedule
Mesh：
Substances：
Year: 2021 PMID： 34187301 PMCID： PMC8437553 DOI： 10.1080/21645515.2021.1926182
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 4.526